Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels

16 Sept 2014

Abstract excerpt

The extended use of brentuximab-vedotin was reported for CD30(+) nonanaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry (IHC) in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semiquantitative CD30 protein assessment by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cutaneous lymphoproliferative disorders research
Share to Lymphoma Diagnosis and Treatment
Share to T-cell and Retrovirus Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25224410
DOI: 10.1182/blood-2014-07-584953

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levelsPMID 25224410Read ↗

CD30 Expression by B and T Cells: A Frequent Finding in Angioimmunoblastic T-Cell Lymphoma and Peripheral T-Cell Lymphoma-Not Otherwise Specified.Semantic proximity Read ↗

CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features.Semantic proximity Read ↗

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomasSemantic proximity Read ↗

Primary Cutaneous CD30 positive Lymphoproliferative Disorders—Current Therapeutic Approach with Focus on Brentuximab VedotinSemantic proximity Read ↗

CD30+ T cell enriched primary cutaneous CD4+ small/medium sized pleomorphic T cell lymphoma: A distinct variant of indolent CD4+ T cell lymphoproliferative disease.Semantic proximity Read ↗

JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.Semantic proximity Read ↗

Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.Semantic proximity Read ↗

Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.Semantic proximity Read ↗

CD30 in Normal and Neoplastic CellsSemantic proximity Read ↗

Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches.Semantic proximity Read ↗

CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma.Semantic proximity Read ↗

CD30—Governor of Memory T Cells?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.